IN THIS ISSUE

Legislation & Regulation
Richard Mark Kirkner

James C. Robinson

Designed to pay for breakthroughs, the new technology add-on (NTAP) ‘bump’ is also too unpredictable, say drug and device groups.

Tomorrow's Medicine
Thomas Morrow, MD

Childhood cancer hasn’t been a big money maker. A not-for-profit helped fund the research that led to the approval of a new drug for neuroblastoma.

News & Commentary

"Arterial kateter (Seldinger)" by Privatarchiv Foto von MrArifnajafov

News & Commentary
Frank Diamond

A blueprint for high-volume, high-quality lung cancer screening that is detecting cancer earlier—and helping to save lives

Clinical Brief

Multiple Sclerosis: New Perspectives on the Patient Journey–2019 Update
Summary of an Actuarial Analysis and Report